机构:[1]Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain;[2]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea;[3]Natl Taiwan Univ, Hosp & Canc Ctr, Taipei, Taiwan;[4]Chinese Univ Hong Kong, Dept Clin Oncol, Key Lab South China, Hong Kong, Hong Kong, Peoples R China;[5]Natl Canc Ctr, Singapore, Singapore;[6]Princess Alexandra Hosp, Brisbane, Qld, Australia;[7]Queensland Univ Technol, Brisbane, Qld, Australia;[8]McGill Univ, Montreal, PQ, Canada;[9]Chris OBrien Lifehouse, Camperdown, NSW, Australia;[10]Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA;[11]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China中山大学肿瘤防治中心
出处:
ISSN:
基金:
Boehringer IngelheimBoehringer Ingelheim
语种:
外文
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类|1 区医学
小类|1 区肿瘤学
最新[2023]版:
大类|1 区医学
小类|1 区肿瘤学
第一作者:
第一作者机构:[1]Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain;
推荐引用方式(GB/T 7714):
Corral J.,Park K.,Yang J. C-H.,et al.Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)[J].ANNALS OF ONCOLOGY.2017,28:-.
APA:
Corral, J.,Park, K.,Yang, J. C-H.,Mok, T.,Tan, E-H....&Zhang, L..(2017).Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7).ANNALS OF ONCOLOGY,28,
MLA:
Corral, J.,et al."Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)".ANNALS OF ONCOLOGY 28.(2017):-